Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of QL1706 Plus Chemotherapy With or Without Bevacizumab for the First-Line Treatment of Recurrent, or Metastatic Cervical Cancer

Next Previous
Trial Profile

A Phase II Study of QL1706 Plus Chemotherapy With or Without Bevacizumab for the First-Line Treatment of Recurrent, or Metastatic Cervical Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Cisplatin (Primary) ; Iparomlimab/tuvonralimab (Primary) ; Paclitaxel (Primary)
  • Indications Adenocarcinoma; Adenosquamous carcinoma; Cervical cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors Qilu Pharmaceutical

Most Recent Events

  • 04 Mar 2024 According to an Qilu Pharmaceutical media release, the results from the Phase II clinical trial (DUBHE-C-206) evaluating the efficacy and safety of Qilu Pharmaceuticals iparomlimab and tuvonralimab (QL1706) in cervical cancer was selected for oral presentation on 8 March, local time.
  • 25 Oct 2023 Updated results presented in an Qilu Pharmaceutical media release.
  • 24 Oct 2023 Results (data cutoff date: 24 Apr 2023) reporting latest efficacy and safety data at a median follow-up time of 14.0 months presented at the 48th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top